Analysis of the Short-Term Efficacy and Adverse Reactions of Albumin-Bound Paclitaxel in the Treatment of Cervical Squamous Cell Carcinoma
Objective:To investigate the short-term efficacy and adverse reactions of albumin-bound paclitaxel in the treatment of cervical squamous cell carcinoma.Methods:From October 2019 to October 2022,124 patients with cervical squamous cell carcinoma treated at our hospital were selected as subjects and randomly divided into two groups(observation group with 62 cases and control group with 62 cases).Both groups received radiotherapy;the control group was treated with paclitaxel combined with cisplatin,while the observation group was given albumin-bound paclitaxel combined with cisplatin.Clinical efficacy and occur-rence of toxic side effects during treatment were recorded after four cycles.Changes in serum tumor markers[squamous cell carcinoma antigen(SCCA),carcinoembryonic antigen(CEA),carbohydrate antigen(CA125)]and T lymphocyte levels(CD3+,CD4+,CD8+)before and after four cycles of treatment were compared between the two groups.Results:After four cycles of treatment,the observation group had a higher treatment efficacy rate(P<0.05).There was no statistically significant difference in the occurrence of toxic side effects between the two groups during treatment(P>0.05).Serum levels of SCCA,CEA,and CA125 decreased in both groups after four cycles of treatment,with a more significant decrease in the observation group(P<0.05).Serum levels of CD3+and CD4+decreased in both groups,with a more significant decrease in the control group,while CD8+levels increased,with a more significant increase in the control group(P<0.05).Conclusion:Albumin-bound paclitaxel is significantly effective in treating cervical squamous cell carci-noma,can effectively control the progression of the disease,and has high safety,making it suitable for clinical promotion.
Albumin-bound paclitaxelCervical squamous cell carcinomaTumor markersToxic and side effectsLymphocytes
国家科技期刊平台
NSTL
万方数据
